Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1982-1993

  Dai, Congxin ^a   Zhang, Bo ^b   Liu, Xiaohai ^a   Guo, Kai ^b   Ma, Sihai ^a   Cai, Feng ^a   Yang, Yakun ^a   Yao, Yong ^a   Feng, Ming ^a   Bao, Xinjie ^a   Deng, Kan ^a   Jiao, Yonghui ^a   Wei, Zhenqing ^a   Junji, Wei ^a   Xing, Bing ^a   Lian, Wei ^a   Wang, Renzhi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b University Liaoning   (China)

Author keywords

folate metabolism; invasive pituitary adenomas; pyrimethamine; refractory; temozolomide

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CATHEPSIN B; CYTOCHROME C; FOLINIC ACID; GELATINASE A; GELATINASE B; HISTONE H2AX; MITOCHONDRIAL ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PYRIMETHAMINE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN ALPHAT3 1; CELL STRAIN ATT 20; CELL STRAIN GH3; CELL STRAIN MMQ; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOSOL; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; HYPOPHYSIS ADENOMA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR CELL; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

FOLATE METABOLISM; INVASIVE PITUITARY ADENOMAS; PYRIMETHAMINE; REFRACTORY; TEMOZOLOMIDE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 7; CASPASE 9; CATHEPSIN B; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DACARBAZINE; DNA DAMAGE; DRUG SYNERGISM; FEMALE; FOLIC ACID ANTAGONISTS; HISTONES; LEUCOVORIN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED NOD; MICE, SCID; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PITUITARY NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMETHAMINE; RATS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881554941     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28199     Document Type: Article

References (43)

1. Asa SL, Ezzat S,. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002; 2: 836-49.
2. Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 2011; 12: 1561-70.
3. Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011; 114: 336-44.
4. Aghi MK,. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 2008; 4: 560-8.
5. Dillard TH, Gultekin SH, Delashaw JJ, et al. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 2011; 14: 80-91.
6. Moshkin O, Syro LV, Scheithauer BW, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 2011; 10: 162-7.
7. Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2012; 15: 97-100.
8. Murakami M, Mizutani A, Asano S, et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 2011; 68: E1761-7.
9. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010; 163: 843-51.
10. Seboxa T, Mao P, Pinchouk N, et al. Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia. Ethiop Med J 2010; 48: 285-91.
11. Iba-Ba J, Ibouili RB, Kombila JB, et al. [Cerebral symptomatic toxoplasmosis treated by sulfadoxine/pyrimethamine treatment. About 6 patients]. Therapie 2008; 63: 71-2.
12. Giammarioli AM, Maselli A, Casagrande A, et al. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res 2008; 68: 5291-300.
13. Chen M, Osman I, Orlow SJ,. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. Mol Cancer Res 2009; 7: 703-12.
14. Ostlund RJ, Leung JT, Hajek SV, et al. Acute stimulated hormone release from cultured GH3 pituitary cells. Endocrinology 1978; 103: 1245-52.
15. Judd AM, Login IS, Kovacs K, et al. Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology 1988; 123: 2341-50.
16. Aoki Y, Iwasaki Y, Katahira M, et al. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: effects of the pituitary adenylate cyclase-Activating polypeptide and vasoactive intestinal polypeptide. Endocrinology 1997; 138: 1930-4.
17. Ma S, Liu X, Yao Y, et al. Effect of temozolomide on cell viability in gonadotroph adenoma cell lines. Oncol Rep 2011; 26: 543-50.
18. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104: 4202-9.
19. Sheehan J, Rainey J, Nguyen J, et al. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2011; 114: 354-8.
20. Chou TC,. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-6.
21. Turner HE, Nagy Z, Esiri MM, et al. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 2000; 85: 2931-5.
22. Gong J, Zhao Y, Abdel-Fattah R, et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 2008; 11: 37-48.
23. Liu W, Kunishio K, Matsumoto Y, et al. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci 2005; 12: 791-4.
24. Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012; 76: 769-75.
25. Kuo LJ, Yang LX,. Gamma-H2AX-A novel biomarker for DNA double-strand breaks. In Vivo 2008; 22: 305-9.
26. Yamauchi T, Yoshida A, Ueda T,. Camptothecin induces DNA strand breaks and is cytotoxic in stimulated normal lymphocytes. Oncol Rep 2011; 25: 347-52.
27. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-32.
28. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 423: 456-61.
29. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998; 391: 496-9.
30. Boulares AH, Yakovlev AG, Ivanova V, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274: 22932-40.
31. Mullen P,. PARP cleavage as a means of assessing apoptosis. Methods Mol Med 2004; 88: 171-81.
32. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011; 117: 454-62.
33. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95: 4592-9.
34. Khorramizadeh MR, Saadat F, Vaezzadeh F, et al. Suppression of telomerase activity by pyrimethamine: implication to cancer. Iran Biomed J 2007; 11: 223-8.
35. Hammond LA, Eckardt JR, Kuhn JG, et al. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 2004; 10: 1645-56.
36. Carmona J, Pabon A, Marquez D, et al. Blood levels of sulfadoxine and pyrimethamine, according to the malaria-treatment response, in two municipalities of Antioquia, Colombia. Rev Panam Salud Publica 2005; 18: 75-83.
37. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360: 2031-8.
38. Klinker H, Langmann P, Richter E,. Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Antimicrob Agents Chemother 1996; 40: 1623-7.
39. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010; 163: 843-51.
40. Kanzawa T, Germano IM, Komata T, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11: 448-57.
41. Giammarioli AM, Gambardella L, Barbati C, et al. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-Apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. Int J Cancer 2012; 131: E337-47.
42. Courtemanche C, Huang AC, Elson-Schwab I, et al. Folate deficiency and ionizing radiation cause DNA breaks in primary human lymphocytes: a comparison. Faseb J 2004; 18: 209-11.
43. Zhang XM, Huang GW, Tian ZH, et al. Folate deficiency induces neural stem cell apoptosis by increasing homocysteine in vitro. J Clin Biochem Nutr 2009; 45: 14-9.